VEGFA and triple-negative breast carcinoma: Additionally, several small-molecule inhibitors of the VEGF pathway appear to have activity in the subset of pre-treated triple-negative breast cancer and definitive studies showing overall survival benefit will be needed prior to re approval [30,31].